nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Adhesion molecules and gene transfer
|
Parkes, Richard J |
|
2000 |
161-162 |
2-3 |
p. 135-152 18 p. |
artikel |
2 |
Adv. Drug Delivery Rev.
|
Welt, Frederick G.P. |
|
1997 |
161-162 |
2-3 |
p. 299- 1 p. |
artikel |
3 |
Amphotericin B colloidal dispersion: an improved antifungal therapy
|
Guo, Luke S.S |
|
2001 |
161-162 |
2-3 |
p. 149-163 15 p. |
artikel |
4 |
Amphotericin B encapsulated in polyethylene glycol-immunoliposomes for infectious diseases
|
Kohno, Shigeru |
|
1997 |
161-162 |
2-3 |
p. 325-329 5 p. |
artikel |
5 |
Analytical challenges in chemical-enzymatic drug targeting
|
Prókai, László |
|
1994 |
161-162 |
2-3 |
p. 301-317 17 p. |
artikel |
6 |
Analytical considerations for microdialysis sampling
|
Davies, Malonne I |
|
2000 |
161-162 |
2-3 |
p. 169-188 20 p. |
artikel |
7 |
A novel chemical delivery system for brain targeting
|
Yoshikawa, Takayoshi |
|
1999 |
161-162 |
2-3 |
p. 255-275 21 p. |
artikel |
8 |
Antibody-directed enzyme prodrug therapy (ADEPT): a review
|
Niculescu-Duvaz, I |
|
1997 |
161-162 |
2-3 |
p. 151-172 22 p. |
artikel |
9 |
Antibody-targeted liposomes: prospects and problems
|
Allen, T.M. |
|
1997 |
161-162 |
2-3 |
p. 243- 1 p. |
artikel |
10 |
Application of lipid microspheres for the treatment of cancer
|
Takenaga, Mitsuko |
|
1996 |
161-162 |
2-3 |
p. 209-219 11 p. |
artikel |
11 |
Application of liposomes for cancer metastasis
|
Oku, Naoto |
|
1997 |
161-162 |
2-3 |
p. 215-223 9 p. |
artikel |
12 |
Application of liposomes to the treatment of liver metastasis
|
Konno, Hiroyuki |
|
1997 |
161-162 |
2-3 |
p. 331-335 5 p. |
artikel |
13 |
Application of microdialysis to characterize drug disposition in tumors
|
Chu, Jianxiong |
|
2000 |
161-162 |
2-3 |
p. 243-253 11 p. |
artikel |
14 |
Approved indications of lipo-PGE1 in Japan
|
Hoshi, K. |
|
1996 |
161-162 |
2-3 |
p. 171-176 6 p. |
artikel |
15 |
A preclinical assessment of the effect of lipo-PGE1 on thrombus formation and thrombus disaggregation
|
Sim, A.K. |
|
1996 |
161-162 |
2-3 |
p. 165-170 6 p. |
artikel |
16 |
A rat extremity soft tissue sarcoma model for the study of systemic treatment with Stealth® liposome-encapsulated tumor necrosis factor-α and cytotoxic agents
|
ten Hagen, Timo L.M. |
|
1997 |
161-162 |
2-3 |
p. 245-256 12 p. |
artikel |
17 |
Biohybrid artificial pancreas based on macrocapsule device
|
Hou, Q.P |
|
1999 |
161-162 |
2-3 |
p. 271-287 17 p. |
artikel |
18 |
Biological factors involved in blood clearance of liposomes by liver
|
Liu, Dexi |
|
1997 |
161-162 |
2-3 |
p. 201-213 13 p. |
artikel |
19 |
Block copolymer micelles as long-circulating drug vehicles
|
Kwon, Glen S. |
|
1995 |
161-162 |
2-3 |
p. 295-309 15 p. |
artikel |
20 |
Blood-brain barrier function of P-glycoprotein
|
Tsuji, Akira |
|
1997 |
161-162 |
2-3 |
p. 287-298 12 p. |
artikel |
21 |
Blood–brain barrier permeability to small and large molecules
|
Cornford, Eain M. |
|
1999 |
161-162 |
2-3 |
p. 145-163 19 p. |
artikel |
22 |
Blood microdialysis in pharmacokinetic and drug metabolism studies
|
Verbeeck, Roger K |
|
2000 |
161-162 |
2-3 |
p. 217-228 12 p. |
artikel |
23 |
Carrier-mediated or specialized transport of drugs across the blood–brain barrier
|
Tsuji, Akira |
|
1999 |
161-162 |
2-3 |
p. 277-290 14 p. |
artikel |
24 |
Cationic lipid–DNA complexes in gene delivery: from biophysics to biological applications
|
Pedroso de Lima, Maria C |
|
2001 |
161-162 |
2-3 |
p. 277-294 18 p. |
artikel |
25 |
Cell cycle regulation and control of angioplasty restenosis
|
Welt, Frederick G.P. |
|
1997 |
161-162 |
2-3 |
p. 301-307 7 p. |
artikel |
26 |
Challenges of turning nucleic acids into therapeutics
|
Mahato, Ram I |
|
2000 |
161-162 |
2-3 |
p. 79-80 2 p. |
artikel |
27 |
Chemical delivery systems and prodrugs of anticonvulsive drugs
|
Shek, Efraim |
|
1994 |
161-162 |
2-3 |
p. 227-241 15 p. |
artikel |
28 |
Chemistry of polyethylene glycol conjugates with biologically active molecules
|
Zalipsky, Samuel |
|
1995 |
161-162 |
2-3 |
p. 157-182 26 p. |
artikel |
29 |
Compartment modeling
|
Holz, Martin |
|
2001 |
161-162 |
2-3 |
p. 249-264 16 p. |
artikel |
30 |
Computer-assisted drug design and selection
|
Kaminski, James J. |
|
1994 |
161-162 |
2-3 |
p. 331-337 7 p. |
artikel |
31 |
Contents of volume 14
|
|
|
1994 |
161-162 |
2-3 |
p. 341-342 2 p. |
artikel |
32 |
Contents of volume 8
|
|
|
1992 |
161-162 |
2-3 |
p. 383- 1 p. |
artikel |
33 |
Contents of volume 10
|
|
|
1993 |
161-162 |
2-3 |
p. 319- 1 p. |
artikel |
34 |
Contents of volume 9
|
|
|
1992 |
161-162 |
2-3 |
p. 318- 1 p. |
artikel |
35 |
Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery
|
Hebert, M.F |
|
1997 |
161-162 |
2-3 |
p. 201-214 14 p. |
artikel |
36 |
Control-relevant modeling in drug delivery
|
Parker, Robert S. |
|
2001 |
161-162 |
2-3 |
p. 211-228 18 p. |
artikel |
37 |
Cubic phase gels as drug delivery systems
|
Shah, Jaymin C |
|
2001 |
161-162 |
2-3 |
p. 229-250 22 p. |
artikel |
38 |
Cumulative author index
|
|
|
1992 |
161-162 |
2-3 |
p. 367-374 8 p. |
artikel |
39 |
Cumulative key word index
|
|
|
1994 |
161-162 |
2-3 |
p. 343-355 13 p. |
artikel |
40 |
Cumulative key word index
|
|
|
1993 |
161-162 |
2-3 |
p. 309-317 9 p. |
artikel |
41 |
Current status and future prospects of parenteral insulin regimens, strategies and delivery systems for diabetes treatment 1 Abbreviations: AIA, antiinsulin antibody; CAPD, continuous ambulatory dialysis; CSII, continuous subcutaneous insulin infusion; DCCT, diabetes control complications trial; FIR, far infrared radiation; GLP1, glucagon-like peptide 1; GH, growth hormone; HbA1c, glycated hemoglobin; IDDM, insulin-dependent diabetes mellitus; IGF1, insulin-like growth factor 1; i.p., intraperitoneal; ISF, interstitial fluid; ISGIID, International Study Group on Implantable Insulin Delivery Devices; i.v., intravenous; MDI, multiple daily injections; NIDDM, non-insulin-dependent diabetes mellitus; PAI1, plasminogen activator inhibitor 1; rh IGF1, recombinant human insulin-like growth factor 1; SHBG, sex hormone binding globulin; SC, subcutaneous; SMBG, self monitoring of blood glucose; TG, triglycerides. 1
|
Jeandidier, Nathalie |
|
1999 |
161-162 |
2-3 |
p. 179-198 20 p. |
artikel |
42 |
Delivery of anti-HIV nucleosides to the central nervous system
|
Gallo, James M. |
|
1994 |
161-162 |
2-3 |
p. 199-209 11 p. |
artikel |
43 |
Delivery of molecular and cellular medicine to solid tumors
|
Jain, Rakesh K |
|
1997 |
161-162 |
2-3 |
p. 71-90 20 p. |
artikel |
44 |
Delivery of peptides and proteins through the blood-brain barrier
|
Bickel, Ulrich |
|
1993 |
161-162 |
2-3 |
p. 205-245 41 p. |
artikel |
45 |
Delivery of tumor suppressor genes to reverse the malignant phenotype
|
Gibson, Neil W |
|
1997 |
161-162 |
2-3 |
p. 119-133 15 p. |
artikel |
46 |
Distribution of lipid microsphere preparations
|
Igarashi, R. |
|
1996 |
161-162 |
2-3 |
p. 147-154 8 p. |
artikel |
47 |
DNA-carrier proteins for targeted gene delivery
|
Uherek, Christoph |
|
2000 |
161-162 |
2-3 |
p. 153-166 14 p. |
artikel |
48 |
(D) Routes of delivery: Case studies
|
de Boer, A.G. |
|
1992 |
161-162 |
2-3 |
p. 237-251 15 p. |
artikel |
49 |
(D) Routes of delivery: Case studies
|
Richardson, Julie L. |
|
1992 |
161-162 |
2-3 |
p. 341-366 26 p. |
artikel |
50 |
(D) Routes of delivery: Case studies
|
Harris, David |
|
1992 |
161-162 |
2-3 |
p. 331-339 9 p. |
artikel |
51 |
(D) Routes of delivery: Case studies
|
Ho, N.F.H. |
|
1992 |
161-162 |
2-3 |
p. 197-236 40 p. |
artikel |
52 |
(D) Routes of delivery: Case studies
|
Edman, Peter |
|
1992 |
161-162 |
2-3 |
p. 165-177 13 p. |
artikel |
53 |
(D) Routes of delivery: Case studies
|
Smith, Philip L. |
|
1992 |
161-162 |
2-3 |
p. 253-290 38 p. |
artikel |
54 |
(D) Routes of delivery: Case studies
|
Cullander, Christopher |
|
1992 |
161-162 |
2-3 |
p. 291-329 39 p. |
artikel |
55 |
(D) Routes of delivery: Case studies
|
Patton, John S. |
|
1992 |
161-162 |
2-3 |
p. 179-196 18 p. |
artikel |
56 |
Drug design strategies for ocular therapeutics
|
Visor, G.C. |
|
1994 |
161-162 |
2-3 |
p. 269-279 11 p. |
artikel |
57 |
Drug targeting and retrometabolic drug design approaches Introduction
|
Bodor, N. |
|
1994 |
161-162 |
2-3 |
p. 157-166 10 p. |
artikel |
58 |
Drug transfer through mucus
|
Khanvilkar, Kavita |
|
2001 |
161-162 |
2-3 |
p. 173-193 21 p. |
artikel |
59 |
Editorial
|
|
|
1997 |
161-162 |
2-3 |
p. 97-98 2 p. |
artikel |
60 |
Editorial
|
|
|
1998 |
161-162 |
2-3 |
p. 121- 1 p. |
artikel |
61 |
Editorial
|
|
|
1999 |
161-162 |
2-3 |
p. 141-142 2 p. |
artikel |
62 |
Editorial
|
|
|
1999 |
161-162 |
2-3 |
p. 143-144 2 p. |
artikel |
63 |
Editorial Board
|
|
|
2007 |
161-162 |
2-3 |
p. ii- 1 p. |
artikel |
64 |
Electrochemotherapy: an emerging drug delivery method for the treatment of cancer
|
Jaroszeski, Mark J |
|
1997 |
161-162 |
2-3 |
p. 185-197 13 p. |
artikel |
65 |
Emulsion formulations as a vector for gene delivery in vitro and in vivo
|
Hara, Toshifumi |
|
1997 |
161-162 |
2-3 |
p. 265-271 7 p. |
artikel |
66 |
Endogenous carriers and ligands in non-immunogenic site-specific drug delivery
|
Vyas, S.P |
|
2000 |
161-162 |
2-3 |
p. 101-164 64 p. |
artikel |
67 |
Endogenous lectins as targets for drug delivery
|
Yamazaki, N. |
|
2000 |
161-162 |
2-3 |
p. 225-244 20 p. |
artikel |
68 |
Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction
|
Thummel, Kenneth E. |
|
1997 |
161-162 |
2-3 |
p. 99-127 29 p. |
artikel |
69 |
Evaluation of an estradiol chemical delivery system (CDS) designed to provide enhanced and sustained hormone levels in the brain
|
Estes, K.S. |
|
1994 |
161-162 |
2-3 |
p. 167-175 9 p. |
artikel |
70 |
Evaluation of nano- and microparticle uptake by the gastrointestinal tract
|
Delie, Florence |
|
1998 |
161-162 |
2-3 |
p. 221-233 13 p. |
artikel |
71 |
Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides
|
Meade, Bryan R. |
|
2007 |
161-162 |
2-3 |
p. 134-140 7 p. |
artikel |
72 |
Exogenous surfactant as a drug delivery agent
|
Haitsma, Jack J. |
|
2001 |
161-162 |
2-3 |
p. 197-207 11 p. |
artikel |
73 |
Fluorocarbons and fluorinated amphiphiles in drug delivery and biomedical research
|
Krafft, Marie Pierre |
|
2001 |
161-162 |
2-3 |
p. 209-228 20 p. |
artikel |
74 |
Forthcoming articles
|
|
|
1992 |
161-162 |
2-3 |
p. 375- 1 p. |
artikel |
75 |
Forthcoming articles
|
|
|
1993 |
161-162 |
2-3 |
p. 301-303 3 p. |
artikel |
76 |
Forthcoming articles
|
|
|
1992 |
161-162 |
2-3 |
p. 313-314 2 p. |
artikel |
77 |
Forthcoming events
|
|
|
1992 |
161-162 |
2-3 |
p. 377-382 6 p. |
artikel |
78 |
Forthcoming events
|
|
|
1992 |
161-162 |
2-3 |
p. 315-317 3 p. |
artikel |
79 |
Forthcoming events
|
|
|
1994 |
161-162 |
2-3 |
p. 340- 1 p. |
artikel |
80 |
Forthcoming events
|
|
|
1993 |
161-162 |
2-3 |
p. 305-307 3 p. |
artikel |
81 |
Forthcoming issues
|
|
|
1994 |
161-162 |
2-3 |
p. 339- 1 p. |
artikel |
82 |
Gene directed enzyme prodrug therapy for cancer
|
McNeish, I.A |
|
1997 |
161-162 |
2-3 |
p. 173-184 12 p. |
artikel |
83 |
Gene manipulation through the use of small interfering RNA (siRNA): From in vitro to in vivo applications
|
Kumar, Lekha Dinesh |
|
2007 |
161-162 |
2-3 |
p. 87-100 14 p. |
artikel |
84 |
Gene therapy of chronic inflammatory disease
|
Hedley, Mary Lynne |
|
2000 |
161-162 |
2-3 |
p. 195-207 13 p. |
artikel |
85 |
Hepatobiliary elimination of cationic drugs: the role of P-glycoproteins and other ATP-dependent transporters
|
Meijer, D.K.F. |
|
1997 |
161-162 |
2-3 |
p. 159-200 42 p. |
artikel |
86 |
How are nucleic acids released in cells from cationic lipid-nucleic acid complexes?
|
Szoka Jr, Francis C. |
|
1997 |
161-162 |
2-3 |
p. 291- 1 p. |
artikel |
87 |
Human immunodeficiency virus protease inhibitors
|
Lin, Jiunn H. |
|
1997 |
161-162 |
2-3 |
p. 215-233 19 p. |
artikel |
88 |
Immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific activation of anticancer prodrugs
|
Storm, Gert |
|
1997 |
161-162 |
2-3 |
p. 225-231 7 p. |
artikel |
89 |
Impact of P450 genetic polymorphism on the first-pass extraction of cardiovascular and neuroactive drugs 1 Supported by the Robert Bosch Foundation, Stuttgart, Germany. 1
|
Fromm, Martin F |
|
1997 |
161-162 |
2-3 |
p. 171-199 29 p. |
artikel |
90 |
Improved brain delivery of antiviral agents through the use of redox targeting
|
Brewster, M.E. |
|
1994 |
161-162 |
2-3 |
p. 177-197 21 p. |
artikel |
91 |
Improvement of oral peptide bioavailability: Peptidomimetics and prodrug strategies
|
Pauletti, Giovanni M. |
|
1997 |
161-162 |
2-3 |
p. 235-256 22 p. |
artikel |
92 |
Inhaled insulin 1 Abbreviations: DM, diabetes mellitus; AIDs, acquired immune deficiency syndrome; SC, subcutaneous; DCCT, Diabetes Control and Complications Trial; IDDM, insulin-dependent diabetes mellitus; NIDDM, non-insulin-dependent diabetes mellitus; i.v., intravenous; DDPC, di-decanoyl-alpha-phosphatidylcholine; AUC, area under the curve; INH, inhaled; C max, maximum serum concentration; C min, minimum serum concentration; T max, time of maximum serum concentration; NS, not significant; HbA1c, hemoglobin A1c; OA, oral agent; SD, standard deviation; MDI, metered dose inhaler; DPI, dry powder inhaler; MMAD, mass median aerodynamic diameter; CMC, critical micelle concentration; SR, sustained release; PLGA, poly lactic acid-co-glycolic acid; GI, gastrointestinal, GSD, geometric standard deviation; TLC, total lung capacity; VC, vital capacity; SMK, smokers; MW, molecular weight; MP, melting point. 1
|
Patton, John S. |
|
1999 |
161-162 |
2-3 |
p. 235-247 13 p. |
artikel |
93 |
Inhibition of DNA repair as a means of increasing the antitumor activity of DNA reactive agents
|
Eileen Dolan, M |
|
1997 |
161-162 |
2-3 |
p. 105-118 14 p. |
artikel |
94 |
Inhibitors of glutathione S-transferases as therapeutic agents
|
Schultz, Mary |
|
1997 |
161-162 |
2-3 |
p. 91-104 14 p. |
artikel |
95 |
Insulin analogs with improved pharmacokinetic profiles
|
Brange, Jens |
|
1999 |
161-162 |
2-3 |
p. 307-335 29 p. |
artikel |
96 |
Interaction of PEG-phospholipid conjugates with phospholipid: implications in liposomal drug delivery
|
Bedu-Addo, Frank K. |
|
1995 |
161-162 |
2-3 |
p. 235-247 13 p. |
artikel |
97 |
Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption
|
Hunter, Janice |
|
1997 |
161-162 |
2-3 |
p. 129-157 29 p. |
artikel |
98 |
Intranasal insulin delivery and therapy 1 Abbreviations: α-CD, α-cyclodextrin; β-CD, β-cyclodextrin; γ-CD, γ-cyclodextrin; AUC, area under the plasma/serum concentration versus time curve; C max, maximum or peak plasma/serum concentration; C min, minimum plasma/serum concentration; DDPC, didecanoyl-L-α-phosphatidylcholine; DM-β-CD, dimethyl-β-cyclodextrin; EDTA, ethylenediaminetetraacetic acid; FITC, fluorescein isothiocyanate; HLB, hydrophile–lipophile balance; hGH, human growth hormone; HP-β-CD, hydroxy-propyl-β-cyclodextrin; HPC, hydroxypropylcellulose; HSA, human serum albumin; Hyaff 11, hyaluronic acid ester; IDDM, insulin-dependent diabetes mellitus; Ig, immunoglobulin; Laureth-9, polyoxyethylene-9-lauryl ether; LPC, lysophosphatidylcholine; LPG, lysophosphatidylglycerol; MCC, microcrystalline cellulose; MTR, mucociliary transport rate; NIDDM, non-insulin-dependent diabetes mellitus; PC, phosphatidylcholine; RAMEB, randomly methylated β-cyclodextrin; SDC, sodium deoxycholate; SGC, sodium glycocholate; STDHF, sodium taurodihydrofusidate; 99mTc, 99mtechnetium; TER, transepithelial resistance. 1
|
Hinchcliffe, Michael |
|
1999 |
161-162 |
2-3 |
p. 199-234 36 p. |
artikel |
99 |
In vitro model for evaluating drug transport across the blood–brain barrier
|
Cecchelli, R |
|
1999 |
161-162 |
2-3 |
p. 165-178 14 p. |
artikel |
100 |
Key word index to volume 9
|
|
|
1992 |
161-162 |
2-3 |
p. 309-312 4 p. |
artikel |
101 |
Lectin-mediated mucosal delivery of drugs and microparticles
|
Clark, M.Ann |
|
2000 |
161-162 |
2-3 |
p. 207-223 17 p. |
artikel |
102 |
Ligand-mediated tissue specific drug delivery
|
Hussain, Nasir |
|
2000 |
161-162 |
2-3 |
p. 95-100 6 p. |
artikel |
103 |
Limethason as a lipid microsphere preparation: An overview
|
Yokoyama, K. |
|
1996 |
161-162 |
2-3 |
p. 195-201 7 p. |
artikel |
104 |
Lipid Assemblies for Drug Delivery
|
|
|
2001 |
161-162 |
2-3 |
p. 137-138 2 p. |
artikel |
105 |
Lipid/DNA complexes as an intermediate in the preparation of particles for gene transfer: an alternative to cationic liposome/DNA aggregates
|
Bally, Marcel B. |
|
1997 |
161-162 |
2-3 |
p. 275-290 16 p. |
artikel |
106 |
Lipid microsphere preparation of a prostacyclin analogue
|
Kurozumi, S. |
|
1996 |
161-162 |
2-3 |
p. 181-187 7 p. |
artikel |
107 |
Lipid microspheres as drug carriers: a pharmaceutical point of view
|
Yamaguchi, Tetsuo |
|
1996 |
161-162 |
2-3 |
p. 117-130 14 p. |
artikel |
108 |
Lipid microspheres (lipid emulsions) as a drug carrier — An overview
|
Mizushima, Yutaka |
|
1996 |
161-162 |
2-3 |
p. 113-115 3 p. |
artikel |
109 |
Lipo-NSAID preparation
|
Ohmukai, O. |
|
1996 |
161-162 |
2-3 |
p. 203-207 5 p. |
artikel |
110 |
Lipo-PGE1 treatment of the neonate with critical congenital heart disease and ductus-arteriosus dependent circulation
|
Momma, Kazuo |
|
1996 |
161-162 |
2-3 |
p. 177-180 4 p. |
artikel |
111 |
Liposome circulation time and tumor targeting: implications for cancer chemotherapy
|
Gabizon, Alberto A. |
|
1995 |
161-162 |
2-3 |
p. 285-294 10 p. |
artikel |
112 |
Liposomes in gene therapy
|
Lasic, D.D. |
|
1996 |
161-162 |
2-3 |
p. 221-266 46 p. |
artikel |
113 |
Liposome turbidimetric assay (LTA)
|
Ueno, Takahisa |
|
1997 |
161-162 |
2-3 |
p. 293-299 7 p. |
artikel |
114 |
Local delivery of chemotherapy: a supplement to existing cancer treatments
|
Hunter, William L |
|
1997 |
161-162 |
2-3 |
p. 199-207 9 p. |
artikel |
115 |
Long-circulating blood pool imaging agents
|
Bogdanov Jr., Alexei A. |
|
1995 |
161-162 |
2-3 |
p. 335-348 14 p. |
artikel |
116 |
Long-circulating iron oxides for MR imaging
|
Weissleder, Ralph |
|
1995 |
161-162 |
2-3 |
p. 321-334 14 p. |
artikel |
117 |
Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals
|
Gabizon, Alberto |
|
1997 |
161-162 |
2-3 |
p. 337-344 8 p. |
artikel |
118 |
Long circulating microparticulate drug carriers
|
Stolnik, S. |
|
1995 |
161-162 |
2-3 |
p. 195-214 20 p. |
artikel |
119 |
Mathematical modeling of bioerodible, polymeric drug delivery systems
|
Siepmann, J. |
|
2001 |
161-162 |
2-3 |
p. 229-247 19 p. |
artikel |
120 |
Mathematical modeling of controlled drug delivery
|
|
|
2001 |
161-162 |
2-3 |
p. 137-138 2 p. |
artikel |
121 |
Mathematical models describing polymer dissolution: consequences for drug delivery
|
Narasimhan, Balaji |
|
2001 |
161-162 |
2-3 |
p. 195-210 16 p. |
artikel |
122 |
MDR2 P-glycoprotein-mediated lipid secretion and its relevance to biliary drug transport
|
Frijters, Charles M.G. |
|
1997 |
161-162 |
2-3 |
p. 201-215 15 p. |
artikel |
123 |
Mechanisms regulating body distribution of nanospheres conditioned with pluronic and tetronic block co-polymers
|
Moghimi, S.M. |
|
1995 |
161-162 |
2-3 |
p. 183-193 11 p. |
artikel |
124 |
Methodological issues in microdialysis sampling for pharmacokinetic studies
|
de Lange, Elizabeth C.M. |
|
2000 |
161-162 |
2-3 |
p. 125-148 24 p. |
artikel |
125 |
Microdialysis and drug delivery to the eye
|
Rittenhouse, Kay D |
|
2000 |
161-162 |
2-3 |
p. 229-241 13 p. |
artikel |
126 |
Microdialysis for pharmacokinetic analysis of drug transport to the brain
|
de Lange, Elizabeth C.M. |
|
1999 |
161-162 |
2-3 |
p. 211-227 17 p. |
artikel |
127 |
Microdialysis in clinical drug delivery studies
|
Müller, Markus |
|
2000 |
161-162 |
2-3 |
p. 255-269 15 p. |
artikel |
128 |
Microdialysis in mice for drug delivery research
|
Boschi, Gabrielle |
|
2000 |
161-162 |
2-3 |
p. 271-281 11 p. |
artikel |
129 |
Microdialysis in peripheral tissues
|
de la Peña, Amparo |
|
2000 |
161-162 |
2-3 |
p. 189-216 28 p. |
artikel |
130 |
Microdialysis in the study of drug transporters in the CNS
|
Sawchuk, Ronald J |
|
2000 |
161-162 |
2-3 |
p. 295-307 13 p. |
artikel |
131 |
Microparticles and polymers for the mucosal delivery of vaccines
|
O'Hagan, Derek T. |
|
1998 |
161-162 |
2-3 |
p. 305-320 16 p. |
artikel |
132 |
Microparticle targeting to M cells
|
Ermak, Thomas H |
|
1998 |
161-162 |
2-3 |
p. 261-283 23 p. |
artikel |
133 |
Modeling in vivo transfer of long-circulating polymers (two classes of long circulating polymers and factors affecting their transfer in vivo)
|
Papisov, Mikhail I. |
|
1995 |
161-162 |
2-3 |
p. 127-139 13 p. |
artikel |
134 |
Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC)
|
Siepmann, J |
|
2001 |
161-162 |
2-3 |
p. 139-157 19 p. |
artikel |
135 |
Modeling transdermal drug release
|
Kalia, Yogeshvar N. |
|
2001 |
161-162 |
2-3 |
p. 159-172 14 p. |
artikel |
136 |
Model systems in iontophoresis — transport efficacy
|
Sage Jr., Burton H. |
|
1992 |
161-162 |
2-3 |
p. 265-287 23 p. |
artikel |
137 |
Modulation of pharmacokinetic behavior of liposomes
|
Scherphof, Gerrit L. |
|
1997 |
161-162 |
2-3 |
p. 179-191 13 p. |
artikel |
138 |
Molecular conformation and structural reorganization near the lipid bilayer surface: biophysical studies of ‘long-circulating’ and DNA-carrying membranes
|
Cevc, Gregor |
|
1997 |
161-162 |
2-3 |
p. 233- 1 p. |
artikel |
139 |
Mucosal immunity of the gastrointestinal tract and oral tolerance
|
Simecka, Jerry W |
|
1998 |
161-162 |
2-3 |
p. 235-259 25 p. |
artikel |
140 |
Nano- and microparticles for the delivery of polypeptides and proteins
|
Couvreur, P. |
|
1993 |
161-162 |
2-3 |
p. 141-162 22 p. |
artikel |
141 |
New lipo-PGE1 using a stable prodrug of prostaglandin E1 (PGE1)
|
Igarashi, R. |
|
1996 |
161-162 |
2-3 |
p. 189-194 6 p. |
artikel |
142 |
Noncompartmentally-based pharmacokinetic modeling
|
Veng-Pedersen, Peter |
|
2001 |
161-162 |
2-3 |
p. 265-300 36 p. |
artikel |
143 |
Non-viral siRNA delivery to the lung
|
Thomas, Mini |
|
2007 |
161-162 |
2-3 |
p. 124-133 10 p. |
artikel |
144 |
Novel approaches to design and deliver safe and effective antiglaucoma agents to the eye
|
Reddy, Indra K. |
|
1994 |
161-162 |
2-3 |
p. 251-267 17 p. |
artikel |
145 |
Oligonucleotide therapeutics: lessons from sterically stabilized liposomes
|
Woodle, M.C. |
|
1997 |
161-162 |
2-3 |
p. 273- 1 p. |
artikel |
146 |
On mathematical models of microdialysis: geometry, steady-state models, recovery and probe radius
|
Ståhle, Lars |
|
2000 |
161-162 |
2-3 |
p. 149-167 19 p. |
artikel |
147 |
Opportunities and challenges for therapeutic gene silencing using RNAi and microRNA technologies
|
Akhtar, Saghir |
|
2007 |
161-162 |
2-3 |
p. 73-74 2 p. |
artikel |
148 |
Oral insulin delivery 1 Abbreviations: GI, gastrointestinal; IDDM, insulin-dependent diabetes mellitus; IU, international units; NIDDM, non-insulin-dependent diabetes mellitus; PIN, phase inversion nanoencapsulation; ZOT, zona occludens toxin. 1
|
Carino, Gerardo P |
|
1999 |
161-162 |
2-3 |
p. 249-257 9 p. |
artikel |
149 |
Oral particulate delivery: status and future trends
|
Chen, Hongming |
|
1998 |
161-162 |
2-3 |
p. 339-350 12 p. |
artikel |
150 |
Pathogenesis of non-insulin-dependent (type II) diabetes mellitus (NIDDM) – genetic predisposition and metabolic abnormalities
|
Jun, Hee-Sook |
|
1999 |
161-162 |
2-3 |
p. 157-177 21 p. |
artikel |
151 |
Pathogenesis, prediction and trials for the prevention of insulin-dependent (type 1) diabetes mellitus 1 Abbreviations: s.c., subcutaneous; i.p., intraperitoneal; i.v., intravenous; IFA, incomplete Freund's adjuvant; DTP, diphtheria-tetanus-pertussis; LCMV, lymphocytic choriomeningitis virus; GAD, glutamic acid decarboxylase; ICA, islet cell autoantibody; JDF, juvenile diabetes foundation; IAA, insulin autoantibody; GAA, glutamic acid decarboxylase autoantibody; DM, diabetes mellitus; RIA, radioimmunoassay; AA, autoantibody; kD, kilodalton; FPIR, first phase insulin release; IIF, indirect immunofluoresence; IGT, impaired glucose tolerance; OGT, oral glucose tolerance. 1
|
Graves, Patricia M. |
|
1999 |
161-162 |
2-3 |
p. 143-156 14 p. |
artikel |
152 |
Penetration of neurotrophins and cytokines across the blood–brain/blood–spinal cord barrier
|
Pan, Weihong |
|
1999 |
161-162 |
2-3 |
p. 291-298 8 p. |
artikel |
153 |
Peptide nucleic acids: versatile tools for gene therapy strategies
|
Dean, David A |
|
2000 |
161-162 |
2-3 |
p. 81-95 15 p. |
artikel |
154 |
P-Glycoprotein, a gatekeeper in the blood–brain barrier
|
Schinkel, Alfred H |
|
1999 |
161-162 |
2-3 |
p. 179-194 16 p. |
artikel |
155 |
Pharmacokinetics of long-circulating liposomes
|
Allen, Theresa M. |
|
1995 |
161-162 |
2-3 |
p. 267-284 18 p. |
artikel |
156 |
Physical properties and tissue distribution of adriamycin encapsulated in polyethyleneglycol-coated liposomes
|
Sadzuka, Yasuyuki |
|
1997 |
161-162 |
2-3 |
p. 257-263 7 p. |
artikel |
157 |
Physiological considerations in the design of particulate dosage forms for oral vaccine delivery
|
Yeh, Ping-Yang |
|
1998 |
161-162 |
2-3 |
p. 123-133 11 p. |
artikel |
158 |
Plasma factors affecting disposition of liposomes
|
Kiwada, Hiroshi |
|
1997 |
161-162 |
2-3 |
p. 193-199 7 p. |
artikel |
159 |
Polymeric carriers for oral uptake of microparticulates
|
Andrianov, Alexander K |
|
1998 |
161-162 |
2-3 |
p. 155-170 16 p. |
artikel |
160 |
Polymeric implants for cancer chemotherapy
|
Fung, Lawrence K. |
|
1997 |
161-162 |
2-3 |
p. 209-230 22 p. |
artikel |
161 |
Polymeric nano- and microparticles for the oral delivery of peptides and peptidomimetics
|
Allémann, Eric |
|
1998 |
161-162 |
2-3 |
p. 171-189 19 p. |
artikel |
162 |
Polymers for controlled parenteral delivery of peptides and proteins
|
Heller, Jorge |
|
1993 |
161-162 |
2-3 |
p. 163-204 42 p. |
artikel |
163 |
Preface
|
Gibson, N.W |
|
1997 |
161-162 |
2-3 |
p. 69-70 2 p. |
artikel |
164 |
Preface
|
Pitt, C.G. |
|
1993 |
161-162 |
2-3 |
p. vii- 1 p. |
artikel |
165 |
Preface
|
Guy, Richard H. |
|
1992 |
161-162 |
2-3 |
p. vii-viii nvt p. |
artikel |
166 |
Preface
|
Torchilin, Vladimir P. |
|
1995 |
161-162 |
2-3 |
p. 125-126 2 p. |
artikel |
167 |
Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems
|
Bodor, Nicholas |
|
1999 |
161-162 |
2-3 |
p. 229-254 26 p. |
artikel |
168 |
Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting
|
Rensen, Patrick C.N |
|
2001 |
161-162 |
2-3 |
p. 251-276 26 p. |
artikel |
169 |
Renal secretion of organic cations: a multistep process
|
Pritchard, John B. |
|
1997 |
161-162 |
2-3 |
p. 231-242 12 p. |
artikel |
170 |
Renal secretion of xenobiotics mediated by P-glycoprotein: Importance to renal function in health and exploitation for targeted drug delivery to epithelial cysts in polycystic kidney disease
|
Simmons, Nicholas L. |
|
1997 |
161-162 |
2-3 |
p. 243-256 14 p. |
artikel |
171 |
Renal tubular secretion of organic anions
|
Dantzler, William H. |
|
1997 |
161-162 |
2-3 |
p. 217-230 14 p. |
artikel |
172 |
Ribozyme and peptide–nucleic acid-based gene therapy
|
Phylactou, Leonidas A |
|
2000 |
161-162 |
2-3 |
p. 97-108 12 p. |
artikel |
173 |
RNA interference and innate immunity
|
Sioud, Mouldy |
|
2007 |
161-162 |
2-3 |
p. 153-163 11 p. |
artikel |
174 |
RNAi therapeutics: Principles, prospects and challenges
|
Aagaard, Lars |
|
2007 |
161-162 |
2-3 |
p. 75-86 12 p. |
artikel |
175 |
RNA repair: a novel approach to gene therapy
|
Watanabe, Takashi |
|
2000 |
161-162 |
2-3 |
p. 109-118 10 p. |
artikel |
176 |
Role of efflux transport across the blood-brain barrier and blood-cerebrospinal fluid barrier on the disposition of xenobiotics in the central nervous system
|
Suzuki, Hiroshi |
|
1997 |
161-162 |
2-3 |
p. 257-285 29 p. |
artikel |
177 |
Role of saccharides for the freeze-thawing and freeze drying of liposome
|
Miyajima, Koichiro |
|
1997 |
161-162 |
2-3 |
p. 151-159 9 p. |
artikel |
178 |
Roles of lipid polymorphism in intracellular delivery
|
Hafez, Ismail M. |
|
2001 |
161-162 |
2-3 |
p. 139-148 10 p. |
artikel |
179 |
Screening and biological evaluation of liposomal formulations containing Adriamycin®
|
Yachi, Kiyoto |
|
1997 |
161-162 |
2-3 |
p. 123-131 9 p. |
artikel |
180 |
Selective boron drug delivery to brain tumors for boron neutron capture therapy
|
Chen, Wei |
|
1997 |
161-162 |
2-3 |
p. 231-247 17 p. |
artikel |
181 |
shRNA and siRNA delivery to the brain
|
Pardridge, William M. |
|
2007 |
161-162 |
2-3 |
p. 141-152 12 p. |
artikel |
182 |
Site-specific insulin conjugates with enhanced stability and extended action profile
|
Uchio, Takashi |
|
1999 |
161-162 |
2-3 |
p. 289-306 18 p. |
artikel |
183 |
Skin biological issues in electrically enhanced transdermal delivery
|
Ledger, Philip W. |
|
1992 |
161-162 |
2-3 |
p. 289-307 19 p. |
artikel |
184 |
Soft anticholinergics
|
Hammer, R.H. |
|
1994 |
161-162 |
2-3 |
p. 281-292 12 p. |
artikel |
185 |
Solid lipid nanoparticles
|
Mehnert, Wolfgang |
|
2001 |
161-162 |
2-3 |
p. 165-196 32 p. |
artikel |
186 |
Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract
|
Ponchel, Gilles |
|
1998 |
161-162 |
2-3 |
p. 191-219 29 p. |
artikel |
187 |
Stability of lipid emulsions for drug delivery
|
Washington, C. |
|
1996 |
161-162 |
2-3 |
p. 131-145 15 p. |
artikel |
188 |
Stealth® liposomes: from theory to product
|
Cˇeh, Boris |
|
1997 |
161-162 |
2-3 |
p. 165-177 13 p. |
artikel |
189 |
Sterically stabilized liposome therapeutics
|
Woodle, Martin C. |
|
1995 |
161-162 |
2-3 |
p. 249-265 17 p. |
artikel |
190 |
Structure-transport relationships in transdermal iontophoresis
|
Yoshida, Nagahiro H. |
|
1992 |
161-162 |
2-3 |
p. 239-264 26 p. |
artikel |
191 |
Studies on two new lymph imaging agents and their clinical application
|
Ma, Yuan-Ming |
|
1997 |
161-162 |
2-3 |
p. 315-323 9 p. |
artikel |
192 |
Supramolecular lipidic drug delivery systems: From laboratory to clinic A review of the recently introduced commercial liposomal and lipid-based formulations of amphotericin B
|
Hillery, Anya M. |
|
1997 |
161-162 |
2-3 |
p. 345-363 19 p. |
artikel |
193 |
Surface-modified liposomes in gamma- and MR-imaging
|
Torchilin, Vladimir P. |
|
1997 |
161-162 |
2-3 |
p. 301-313 13 p. |
artikel |
194 |
Systemic siRNA delivery via hydrodynamic intravascular injection
|
Lewis, David L. |
|
2007 |
161-162 |
2-3 |
p. 115-123 9 p. |
artikel |
195 |
Targeting efficiency of PEG-immunoliposome-conjugated antibodies at PEG terminals
|
Maruyama, Kazuo |
|
1997 |
161-162 |
2-3 |
p. 235-242 8 p. |
artikel |
196 |
Targeting penicillins to the central nervous system: chemical delivery systems and redox analogs
|
Pop, E. |
|
1994 |
161-162 |
2-3 |
p. 211-226 16 p. |
artikel |
197 |
The barrier function of CYP3A4 and P-glycoprotein in the small bowel
|
Watkins, Paul B |
|
1997 |
161-162 |
2-3 |
p. 161-170 10 p. |
artikel |
198 |
The blood–brain barrier efflux transporters as a detoxifying system for the brain
|
Terasaki, Tetsuya |
|
1999 |
161-162 |
2-3 |
p. 195-209 15 p. |
artikel |
199 |
The brain-targeted delivery of dopamine using a redox-based chemical delivery system
|
Simpkins, James W. |
|
1994 |
161-162 |
2-3 |
p. 243-249 7 p. |
artikel |
200 |
The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres
|
Gref, R. |
|
1995 |
161-162 |
2-3 |
p. 215-233 19 p. |
artikel |
201 |
The design and development of DaunoXome® for solid tumor targeting in vivo
|
Forssen, Eric A. |
|
1997 |
161-162 |
2-3 |
p. 133-150 18 p. |
artikel |
202 |
The distribution and chemical kinetics of prostaglandin E1 in lipid emulsions
|
Teagarden, Dirk L. |
|
1996 |
161-162 |
2-3 |
p. 155-164 10 p. |
artikel |
203 |
The effect of physical barriers and properties on the oral absorption of particulates
|
Norris, Daniel A |
|
1998 |
161-162 |
2-3 |
p. 135-154 20 p. |
artikel |
204 |
The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavailability in humans
|
Wilkinson, Grant R |
|
1997 |
161-162 |
2-3 |
p. 129-159 31 p. |
artikel |
205 |
Theoretical models for iontophoretic delivery
|
Kasting, Gerald B. |
|
1992 |
161-162 |
2-3 |
p. 177-199 23 p. |
artikel |
206 |
The pharmaceutics and delivery of therapeutic polypeptides and proteins
|
Talmadge, James E. |
|
1993 |
161-162 |
2-3 |
p. 247-299 53 p. |
artikel |
207 |
The pharmacokinetics and transdermal delivery of loteprednol etabonate and related soft steroids
|
Loftsson, Thorsteinn |
|
1994 |
161-162 |
2-3 |
p. 293-299 7 p. |
artikel |
208 |
The preparation and characterization of polymeric antigen delivery systems for oral administration
|
Singh, Manmohan |
|
1998 |
161-162 |
2-3 |
p. 285-304 20 p. |
artikel |
209 |
Therapeutic potential for microRNAs
|
Esau, Christine C. |
|
2007 |
161-162 |
2-3 |
p. 101-114 14 p. |
artikel |
210 |
The role of CpG motifs in immunostimulation and gene therapy
|
Scheule, Ronald K |
|
2000 |
161-162 |
2-3 |
p. 119-134 16 p. |
artikel |
211 |
The role of electroosmotic flow in transdermal iontophoresis
|
Pikal, Michael J. |
|
1992 |
161-162 |
2-3 |
p. 201-237 37 p. |
artikel |
212 |
The use of microdialysis in CNS drug delivery studies
|
Hammarlund-Udenaes, Margareta |
|
2000 |
161-162 |
2-3 |
p. 283-294 12 p. |
artikel |
213 |
The use of phage display for the development of tumour targeting agents
|
Nilsson, Fredrik |
|
2000 |
161-162 |
2-3 |
p. 165-196 32 p. |
artikel |
214 |
Three-dimensional liposome networks: freeze fracture electron microscopical evaluation of their structure and in vitro analysis of release of hydrophilic markers
|
Brandl, M. |
|
1997 |
161-162 |
2-3 |
p. 161-164 4 p. |
artikel |
215 |
Tissue engineering via local gene delivery:
|
Bonadio, Jeffrey |
|
2000 |
161-162 |
2-3 |
p. 185-194 10 p. |
artikel |
216 |
Toward development of a non-viral gene therapeutic
|
Smith, Janet |
|
1997 |
161-162 |
2-3 |
p. 135-150 16 p. |
artikel |
217 |
Toward lung-selective β2-adrenergic bronchodilator prodrugs
|
Svensson, Leif-Å. |
|
1994 |
161-162 |
2-3 |
p. 319-330 12 p. |
artikel |
218 |
Towards new products for human health
|
Hirota, Sadao |
|
1997 |
161-162 |
2-3 |
p. 121-122 2 p. |
artikel |
219 |
Toxicogenomics of non-viral drug delivery systems for RNAi: Potential impact on siRNA-mediated gene silencing activity and specificity
|
Akhtar, Saghir |
|
2007 |
161-162 |
2-3 |
p. 164-182 19 p. |
artikel |
220 |
Transcriptional control: an essential component of cancer gene therapy strategies?
|
Harrington, Kevin J. |
|
2000 |
161-162 |
2-3 |
p. 167-184 18 p. |
artikel |
221 |
Transdermal ion migration
|
Bradley Phipps, J. |
|
1992 |
161-162 |
2-3 |
p. 137-176 40 p. |
artikel |
222 |
Treatment of type I diabetes using encapsulated islets 1 Abbreviations: Tx, transplantation; IEQ, islet equivalent; BUN, blood urea nitrogen. 1
|
Soon-Shiong, Patrick |
|
1999 |
161-162 |
2-3 |
p. 259-270 12 p. |
artikel |
223 |
Uptake and adjuvant activity of orally delivered saponin and ISCOM™ vaccines
|
Sjölander, Anders |
|
1998 |
161-162 |
2-3 |
p. 321-338 18 p. |
artikel |
224 |
Use of microdialysis in drug delivery studies
|
Elmquist, William F |
|
2000 |
161-162 |
2-3 |
p. 123-124 2 p. |
artikel |
225 |
Use of polyoxyethylene-lipid conjugates as long-circulating carriers for delivery of therapeutic and diagnostic agents
|
Trubetskoy, Vladimir S. |
|
1995 |
161-162 |
2-3 |
p. 311-320 10 p. |
artikel |
226 |
Vector-mediated drug delivery to the brain
|
Pardridge, William M. |
|
1999 |
161-162 |
2-3 |
p. 299-321 23 p. |
artikel |
227 |
Virosomes: evolution of the liposome as a targeted drug delivery system
|
Kaneda, Yasufumi |
|
2000 |
161-162 |
2-3 |
p. 197-205 9 p. |
artikel |
228 |
What are the pathways of iontophoretic current flow through mammalian skin?
|
Cullander, Christopher |
|
1992 |
161-162 |
2-3 |
p. 119-135 17 p. |
artikel |
229 |
Which polymers can make nanoparticulate drug carriers long-circulating?
|
Torchilin, Vladimir P. |
|
1995 |
161-162 |
2-3 |
p. 141-155 15 p. |
artikel |